Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease

Journal of Diabetes Investigation

Volumn 4, Issue 1, 2013, Pages 4-18

  Vinik, Aaron I ^a   Erbas, Tomris ^b   Casellini, Carolina M ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiac autonomic neuropathy; Inflammation; Pathogenesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GLUCOSE;

ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL PRACTICE; DIABETIC PATIENT; DIAGNOSTIC TEST; DOPPLER ECHOCARDIOGRAPHY; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SILENT MYOCARDIAL ISCHEMIA; SUDDEN DEATH;

EID: 84873145413     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12042     Document Type: Review

References (66)

1. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic Autonomic Neuropathy. Diabetes Care 2003; 26: 1553-1579.
2. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895-1901.
3. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-397.
4. Saravia F, Homo-Delarche F. Is innervation an early target in autoimmune diabetes? Trends Immunol 2003; 24: 574-579.
5. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
6. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-428.
7. Tracey KJ. Immune cells exploit a neural circuit to enter the CNS. Cell 2012; 148: 392-394.
8. Watkins LR, Goehler LE, Relton JK, et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995; 183: 27-31.
9. Hansen MK, O'Connor KA, Goehler LE, et al. The contribution of the vagus nerve in interleukin-1beta-induced fever is dependent on dose. Am J Physiol Regul Integr Comp Physiol 2001; 280: R929-R934.
10. Goehler LE, Relton JK, Dripps D, et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res Bull 1997; 43: 357-364.
11. Vinik A, Maser R, Ziegler D. Autonomic Imbalance: Prophet of Doom or Scope for Hope? Diabet Med 2011; 28: 643-651.
12. Wu JS, Yang YC, Lin TS, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab 2007; 92: 3885-3889.
13. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48: 1637-1644.
14. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
15. Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017.
16. Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 2009; 106: 20021-20026.
17. Witzke KA, Vinik AI, Grant LM, et al. Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care 2011; 34: 1617-1621.
18. Lieb D, Parson H, Mamikunian G, et al. Cardiac Autonomic Imbalance in Newly Diagnosed and Established Diabetes Is Associated with Markers of Adipose Tissue Inflammation. Exp Diabetes Res 2011; 2012: 1-8.PMID:22110481
19. von Känel R, Nelesen RA, Mills PJ, et al. Relationship between heart rate variability, interleukin-6, and soluble tissue factor in healthy subjects. Brain Behav Immun 2008; 22: 461-468.
20. Thayer JF, Fischer JE. Heart rate variability, overnight urinary norepinephrine and C-reactive protein: evidence for the cholinergic anti-inflammatory pathway in healthy human adults. J Intern Med 2009; 265: 439-447.
21. Wakabayashi S, Aso Y. Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care 2004; 27: 2392-2397.
22. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423.
23. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995; 45: 773-780.
24. Ziegler D, Gries FA, Muhlen H, et al. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 1993; 19: 143-151.
25. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-653.
26. Pop-Busui R, Evans G, Gerstein H, et al., the ACCORD Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578-1584.
27. Calles-Escandon J, Lovato L, Simons-Morton D, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics. Diabetes Care 2010; 33: 721-727.
28. Huikuri HV, Jokinen V, Syvanne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 1979-1985.
29. Janszky I, Ericson M, Mittleman MA, et al. Heart rate variability in long-term risk assessment in middle-aged women with coronary heart disease: The Stockholm Female Coronary Risk Study. J Intern Med 2004; 255: 13-21.
30. Hadase M, Azuma A, Zen K, et al. Very low frequency power of heart rate variability is a powerful predictor of clinical prognosis in patients with congestive heart failure. Circ J 2004; 68: 343-347.
31. Beijers HJ, Ferreira I, Bravenboer B, et al. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care 2009; 32: 1698-1703.
32. Ziegler D, Zentai CP, Perz S, et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556-561.
33. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107: 565-570.
34. Orchard TJ, Lloyd CE, Maser RE, et al. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996; 34: S165-S171.
35. Vinik AI, Maser RE, Ziegler D. Neuropathy: The Crystal Ball for Cardiovascular Disease? Diabetes Care 2010; 33: 1688-1690.
36. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. Diabetes Care 2004; 27: 1954-1961.
37. Kempler P, Tesfaye S, Chaturvedi N, et al. the EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2001; 19: 900-909.
38. Lykke JA, Tarnow L, Parving HH, et al. A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008; 68: 654-659.
39. Singh JP, Larson MG, O'Donnell CJ, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309-312.
40. Hage FG, Iskandrian AE. Cardiovascular imaging in diabetes mellitus. J Nucl Cardiol 2011; 18: 959-965.
41. Nauman J, Janszky I, Vatten LJ, et al. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306: 2579-2587.
42. Burgos LG, Ebert TJ, Assiddao C, et.al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989; 70: 591-597.
43. Kitamura A, Hoshino T, Kon T, et al. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 2000; 92: 1311-1318.
44. Sobotka PA, Liss HP, Vinik AI. Impaired hypoxic ventilatory drive in diabetic patients with autonomic neuropathy. J Clin Endocrinol Metab 1986; 62: 658-663.
45. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Auton Nerv Syst 1996; 58: 123-124.
46. Low PA, Walsh JC, Huang CY, et al. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. Brain 1975; 98: 341-356.
47. Margolis JR, Kannel WS, Feinleib M, et al. Clinical features of unrecognized myocardial infarction-silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973; 32: 1-7.
48. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000; 283: 3223-3229.
49. Shakespeare CF, Katritsis D, Crowther A, et al. Differences in autonomic nerve function in patients with silent and symptomatic myocardial ischaemia. Br Heart J 1994; 71: 22-29.
50. Mustonen J, Uusitupa M, Lansimies E, et al. Autonomic nervous function and its relationship to cardiac performance in middle-aged diabetic patients without clinically evident cardiovascular disease. J Intern Med 1992; 232: 65-72.
51. Didangelos TP, Arsos GA, Karamitsos DT, et al. Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care 2003; 26: 1955-1960.
52. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214-1220.
53. Ansari M, Alexander M, Tutar A, et al. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J 2003; 146: 115-120.
54. Mandinov L, Eberli FR, Seiler C, et al. Diastolic heart failure. Cardiovasc Res 2000; 45: 813-825.
55. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes and hypertension. Clin Exp Hypertens 2001; 23: 45-55.
56. Akselrod S, Gordon D, Ubel FA, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220-222.
57. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.
58. Bernardi L, Spallone V, Stevens M, et al. Investigation methods for cardiac autonomic function in human research studies. Diabetes Metab Res Rev 2011; 27: 654-664.
59. Motooka M, Koike H, Yokoyama T, et al. Effect of dog-walking on autonomic nervous activity in senior citizens. Med J Aust 2006; 184: 60-63.
60. Morrison S, Colberg SR, Mariano M, et al. Balance Training Reduces Falls Risk in Older Individuals With Type 2 Diabetes. Diabetes Care 2010; 33: 748-50.
61. Vinik AI, Erbas T. Cardiovascular autonomic neuropathy: diagnosis and management. Curr Diab Rep 2006; 6: 424-430.
62. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999; 353: 617-622.
63. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
64. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997; 20: 369-373.
65. Vinik A. The Question Is, My Dear Watson, Why Did the Dog Not Bark?: The Joslin 50-Year Medalist Study. Diabetes Care 2011; 34: 1060-1063.
66. Vinik AI, Casellini C, Nevoret M-L. Chapter 31 - Diabetic Neuropathies. In www.endotext.org website, version 9/26/2012, published by MDTEXT.com, Inc., S. Darmouth, MA.